| A19 | In-depth single-cell analysis of translation-competent HIV-1 reservoirs identifies cellular sources of residual viremia and rebound viruses | E-poster | Characterizing HIV/SIV reservoirs and rebounding virus |
| A19 | Proviral turnover pre-ART is dynamic and variable between hosts, impacting reservoir composition | E-poster | Characterizing HIV/SIV reservoirs and rebounding virus |
| A19 | Subtype D HIV-1 reservoir levels and viral sequence profiles in Rakai, Uganda | E-poster | Characterizing HIV/SIV reservoirs and rebounding virus |
| A19 | Translation-competent expanded HIV clones are phenotypically diverse | E-poster | Characterizing HIV/SIV reservoirs and rebounding virus |
| B76 | Cardiometabolic risk factor comparison between foreign and native born African American persons with HIV infection in a U.S. urban healthcare setting | E-poster | Clinical issues in other vulnerable populations |
| B71 | Correlates of medication for opioid use disorder treatment retention in patients with HIV and opioid use disorder in Northern Viet Nam | E-poster | Clinical issues in people who use drugs |
| B61 | Once-daily integrase inhibitor (INSTI) with boosted darunavir is non-inferior to standard of care in virologically suppressed children, Week 48 results of the SMILE PENTA-17 TRIAL | E-poster | Clinical trials in paediatric and adolescent populations |
| B61 | Weight gain in children and adolescents on dolutegravir vs standard of care in the ODYSSEY trial | E-poster | Clinical trials in paediatric and adolescent populations |
| B61 | Effect of dolutegravir on folate and vitamin B12 status among HIV-infected children and adolescents in the ODYSSEY trial | E-poster | Clinical trials in paediatric and adolescent populations |
| B61 | Virological failures and genotypic resistance in children and adolescents randomised to dolutegravir-based ART vs. standard-of-care in the ODYSSEY trial | E-poster | Clinical trials in paediatric and adolescent populations |